SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-22-001828
Filing Date
2022-02-18
Accepted
2022-02-18 09:02:38
Documents
14
Period of Report
2022-02-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K gtbp_8k.htm   iXBRL 8-K 24531
  Complete submission text file 0001654954-22-001828.txt   148663

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA gtbp-20220214.xsd EX-101.SCH 5843
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE gtbp-20220214_lab.xml EX-101.LAB 14755
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE gtbp-20220214_cal.xml EX-101.CAL 904
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gtbp-20220214_pre.xml EX-101.PRE 9377
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE gtbp-20220214_def.xml EX-101.DEF 2109
8 EXTRACTED XBRL INSTANCE DOCUMENT gtbp_8k_htm.xml XML 3587
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 22651005
SIC: 2834 Pharmaceutical Preparations